Wang Ao, Quint Elchanan, Kukeev Ivan, Agassi Ravit, Belochitski Olga, Barski Gay, Vaynshtein Julie
Medical School for International Health Ben-Gurion University of the Negev, Be'er Sheva 8410501, Israel.
Department of General Surgery B Soroka University Medical Center, Be'er Sheva 8410101, Israel.
Int J Breast Cancer. 2024 Jun 18;2024:5551907. doi: 10.1155/2024/5551907. eCollection 2024.
Intraoperative radiation therapy (IORT) has gained popularity in recent years as an alternative to external beam whole breast radiation therapy (WBRT) for early-stage breast cancer. Here, we report 43-month recurrence and survival outcomes in a multiethnic cohort treated with IORT in a clinical context. Two hundred and eleven patients with low-risk features were treated with IORT for early-stage breast cancer from 2014 to 2021. Selection criteria were based on Group Europeen de Curietherapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) guidelines: preferably unifocal intraductal carcinoma (IDC), aged > 50, tumor size ≤ 2.0 cm, and without lymph node involvement. All patients received 20 Gy of radiation dose during the lumpectomy. Information on patient and tumor characteristics was collected. The mean age of this cohort was 67.5 years; 95.2% of patients are Jewish, and the rest are Bedouins (4.7%). Most tumors were intraductal carcinoma (97.2%) and stage 1 (94.8%). The mean follow-up time was 43.4 months. Bedouins had larger tumor sizes (mean 1.21 vs. 1.13 cm) and were younger at diagnosis than Jewish patients (mean 65.4 vs. 67.6 years), although the differences are not significant. The overall recurrence rate was 1.4%. One case of local recurrence (0.5%) and two cases of metastasis (0.9%) were observed during the study period. One patient died from metastasis. Our findings suggest that IORT in selected low-risk patients can achieve an excellent prognosis with low rates of recurrence and metastasis.
术中放疗（IORT）近年来作为早期乳腺癌外照射全乳放疗（WBRT）的替代方法而受到欢迎。在此，我们报告在临床环境中接受IORT治疗的多民族队列的43个月复发和生存结果。2014年至2021年，211例具有低风险特征的患者接受了早期乳腺癌的IORT治疗。选择标准基于欧洲居里治疗协作组-欧洲放射肿瘤学会（GEC-ESTRO）指南：最好为单灶性导管内癌（IDC），年龄>50岁，肿瘤大小≤2.0 cm，且无淋巴结受累。所有患者在肿块切除术中接受20 Gy的放射剂量。收集了患者和肿瘤特征的信息。该队列的平均年龄为67.5岁；95.2%的患者为犹太人，其余为贝都因人（4.7%）。大多数肿瘤为导管内癌（97.2%）且为1期（94.8%）。平均随访时间为43.4个月。贝都因人的肿瘤尺寸较大（平均1.21 cm对1.13 cm），诊断时比犹太患者年轻（平均65.4岁对67.6岁），尽管差异不显著。总复发率为1.4%。在研究期间观察到1例局部复发（0.5%）和2例转移（0.9%）。1例患者死于转移。我们的研究结果表明，在选定的低风险患者中，IORT可以实现低复发率和转移率的良好预后。
